Diadem Overview

  • Founded

  • 2012

Founded
  • Status

  • Private

  • Employees

  • 2

Employees
  • Latest Deal Type

  • Grant

  • Latest Deal Amount

  • $2.5M

  • Investors

  • 3

Diadem General Information

Description

Developer of a diagnostic platform designed to predict Alzheimer's disease years in advance. The company's platform offers predictions, monitoring, diagnosis, and successful drug development for Alzheimer's disease, enabling Alzheimer's patients to get treatment at a cost-effective price.

Contact Information

Website
www.diademdx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Diagnostic Equipment
Primary Office
  • Via Ceresio 7
  • Milan
  • Italy

Diadem Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Diadem Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 07-Sep-2022 $2.5M 0000 Completed Generating Revenue
2. Later Stage VC 28-Mar-2022 000.00 0000 Completed Generating Revenue
1. Later Stage VC (Series A) 21-Dec-2018 $1.7M $1.7M Completed Pre-Clinical Trials
To view Diadem’s complete valuation and funding history, request access »

Diadem Patents

  • 21

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Diadem Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230054852-A1 P53 post-translational modifications as markers in the diagnosis and prognosis of a neurodegenerative disease Pending 30-Jul-2020 00000000000
AU-2021317020-A1 P53 post-translational modifications as markers in the diagnosis and prognosis of a neurodegenerative disease Pending 30-Jul-2020 00000000000
CA-3190285-A1 P53 post-translational modifications as markers in the diagnosis and prognosis of a neurodegenerative disease Pending 30-Jul-2020 00000000000
US-20220034912-A1 P53 post-translational modifications as markers in the diagnosis and prognosis of a neurodegenerative disease Pending 30-Jul-2020 00000000000
AU-2019432635-A1 P53 peptides as markers in the diagnosis and prognosis of alzheimer's disease Pending 06-Mar-2019 C07K14/4746
To view Diadem’s complete patent history, request access »

Diadem Executive Team (9)

Name Title Board Seat Contact Info
Paul Kinnon Chief Executive Officer & Board Member
Daniela Uberti Co-Founder
Simona Piccirella Ph.D Vice President, Product Development and Operations
Samuel Agus Chief Medical Officer
You’re viewing 4 of 9 executive team members. Get the full list »

Diadem Board Members (9)

Name Representing Role Since
Diana Saraceni Panakes Partners Board Member 000 0000
Epstein Sheldon Self Board Member 000 0000
Francesco Granata MD Self Board Member 000 0000
Gerald Möller Diadem Chairman 000 0000
Mario Scuderi CDP Venture Capital Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Diadem Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Diadem Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
The National Institute on Aging (NIA) Government 000 0000 000000 0
CDP Venture Capital Venture Capital Minority 000 0000 000000 0
Panakes Partners Venture Capital Minority 000 0000 000000 0
To view Diadem’s complete investors history, request access »

Ready to get started?

Request a free trial